Profile data is unavailable for this security.
About the company
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
- Revenue in USD (TTM)19.08m
- Net income in USD-50.52m
- Incorporated2012
- Employees166.00
- LocationProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
- Phone+31 854894932
- Websitehttps://www.proqr.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | 7.14m | -156.09m | 144.19m | 181.00 | -- | 0.616 | -- | 20.20 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 144.79m | 33.00 | -- | 7.06 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 145.35m | 62.00 | -- | 2.62 | -- | 190.75 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 145.73m | 21.00 | -- | 1.83 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 147.68m | 147.00 | -- | 1.04 | -- | 15.89 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 149.54m | 32.00 | -- | 38.67 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 150.69m | 105.00 | -- | -- | -- | 125.57 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 152.04m | 61.00 | -- | 1.63 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 152.96m | 140.00 | -- | 0.8587 | -- | 1.35 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| ProQR Therapeutics NV | 19.08m | -50.52m | 153.80m | 166.00 | -- | 2.32 | -- | 8.06 | -0.4858 | -0.4858 | 0.1837 | 0.6288 | 0.139 | -- | 9.70 | 114,910.10 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 160.06m | 31.00 | -- | 3.42 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 161.78m | 6.00 | -- | 3.86 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to ProQR Therapeutics NV's reporting currency: US Dollar USD
24.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 30 Sep 2025 | 6.25m | 5.94% |
| Privium Fund Management BVas of 31 Dec 2025 | 5.36m | 5.09% |
| abrdn, Inc.as of 31 Dec 2025 | 2.95m | 2.80% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 2.45m | 2.33% |
| Sio Capital Management LLCas of 30 Sep 2025 | 2.08m | 1.97% |
| Kynam Capital Management LPas of 30 Sep 2025 | 1.65m | 1.57% |
| DAFNA Capital Management LLCas of 30 Sep 2025 | 1.57m | 1.49% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 1.36m | 1.29% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2025 | 1.25m | 1.18% |
| Platinum Investment Management Ltd.as of 31 Dec 2025 | 1.24m | 1.17% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
